Discovery of ARF1-targeting inhibitor demethylzeylasteral as a potential agent against breast cancer  

作　　者：Jie Chang Ruirui Yang Lifan Chen Zisheng Fan Jingyi Zhou Hao Guo Yinghui Zhang Yadan Liu Guizhen Zhou Keke Zhang Kaixian Chen Hualiang Jiang Mingyue Zheng Sulin Zhang 

机构地区：[1]School of Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China [2]Drug Discovery and Design Center,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China [3]University of Chinese Academy of Sciences,Beijing 100049,China [4]Shanghai Institute for Advanced Immunochemical Studies,and School of Life Science and Technology,ShanghaiTech University,Shanghai 200031,China

出　　处：《Acta Pharmaceutica Sinica B》2022年第5期2619-2622,共4页药学学报（英文版）

基　　金：supported by the National Natural Science Foundation of China (81903639 to Sulin Zhang,China);Lingang Laboratory (LG202102-01-02 to Mingyue Zheng,China,LG-QS-202204-01 to Sulin Zhang,China);Shanghai Municipal Science and Technology Major Project (Hualiang Jiang,China);Shanghai Sailing Program (19YF1457800 to Sulin Zhang,China)。

摘　　要：To the Editor:ADP-ribosylation factor 1 (ARF1) plays a critical role in regulating vesicle formation and transport1. The dysregulation of ARF1 expression and/or activity is involved in many human cancers, such as breast cancer2,3. Therefore, ARF1 is one of the promising therapeutic targets for cancer treatment.

关 键 词：ADP-ribosylation factor 1 Breast cancer DEMETHYLZEYLASTERAL Virtual screening 

分 类 号：R96[医药卫生—药理学]